TY - JOUR
T1 - Diagnostic accuracy of F-18 FDG-PET in the assessment of posttherapeutic recurrence of head and neck cancer
AU - Cheon, Gi Jeong
AU - Chung, June Key
AU - So, Young
AU - Choi, Joon Young
AU - Kim, Byung Tae
AU - Jeong, Jae Min
AU - Lee, Dong Soo
AU - Baek, Chung Hwan
AU - Kim, Kwang Hyun
AU - Lee, Myung Chul
PY - 1999
Y1 - 1999
N2 - The purpose of this study was to compare whole-body fluorine-18-fluorodeoxyglucose positron emission tomography (F-18 FDG-PET) with conventional imaging modalities (CI: CT/MRI) in the detection of recurrent head and neck cancer. Whole-body F-18 FDG-PET was performed in 45 patients (recurrence = 39; no recurrence = 16) with previous head and neck cancer. We compared detectability by the period from initial cancer treatment and treatment modalities. Thirty were PET-positive and 15 were PET-negative. The sensitivity, specificity, and accuracy of PET were 97%, 88%, and 93%, respectively (corresponding figures of CI were 73%, 85%, and 77%). In 18 patients who underwent PET less than 3 months after the completion of cancer treatment, the sensitivity, specificity, and accuracy were 100%, 86%, and 94%, while for CI, the corresponding figures were 67%, 71%, and 69%. In 18 patients who had undergone surgery, PET results were 14 true positive and 4 were true negative; significantly higher detectability than CI. Among the patients who were evaluated for more than 6 months or treated by radiotherapy without surgery, diagnostic accuracy was almost the same. Whole body F-18 FDG-PET was a valuable tool in the evaluation of post-therapeutic recurrence of head and neck cancer.
AB - The purpose of this study was to compare whole-body fluorine-18-fluorodeoxyglucose positron emission tomography (F-18 FDG-PET) with conventional imaging modalities (CI: CT/MRI) in the detection of recurrent head and neck cancer. Whole-body F-18 FDG-PET was performed in 45 patients (recurrence = 39; no recurrence = 16) with previous head and neck cancer. We compared detectability by the period from initial cancer treatment and treatment modalities. Thirty were PET-positive and 15 were PET-negative. The sensitivity, specificity, and accuracy of PET were 97%, 88%, and 93%, respectively (corresponding figures of CI were 73%, 85%, and 77%). In 18 patients who underwent PET less than 3 months after the completion of cancer treatment, the sensitivity, specificity, and accuracy were 100%, 86%, and 94%, while for CI, the corresponding figures were 67%, 71%, and 69%. In 18 patients who had undergone surgery, PET results were 14 true positive and 4 were true negative; significantly higher detectability than CI. Among the patients who were evaluated for more than 6 months or treated by radiotherapy without surgery, diagnostic accuracy was almost the same. Whole body F-18 FDG-PET was a valuable tool in the evaluation of post-therapeutic recurrence of head and neck cancer.
KW - F-18-fluorodeoxyglucose (FDG)
KW - Head and Neck Cancer
KW - Positron Emission Tomography (PET)
KW - Recurrence
UR - https://www.scopus.com/pages/publications/0000994436
U2 - 10.1016/S1095-0397(99)00023-0
DO - 10.1016/S1095-0397(99)00023-0
M3 - Article
AN - SCOPUS:0000994436
SN - 1095-0397
VL - 2
SP - 197
EP - 204
JO - Clinical Positron Imaging (Netherlands)
JF - Clinical Positron Imaging (Netherlands)
IS - 4
ER -
